Study on the improvement effect and mechanism of fuling and Chenpi tea combined with flexible fasting technology on the health status of simple obesity patients with phlegm-dampness constitution

注册号:

Registration number:

ITMCTR2200006355

最近更新日期:

Date of Last Refreshed on:

2022-07-09

注册时间:

Date of Registration:

2022-07-09

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

“茯苓陈皮饮配合柔性辟谷技术”对痰湿体质单纯性肥胖患者健康状况的改善作用与机制研究

Public title:

Study on the improvement effect and mechanism of fuling and Chenpi tea combined with flexible fasting technology on the health status of simple obesity patients with phlegm-dampness constitution

注册题目简写:

English Acronym:

研究课题的正式科学名称:

“茯苓陈皮饮配合柔性辟谷技术”对痰湿体质单纯性肥胖患者健康状况的改善作用与机制研究

Scientific title:

Study on the improvement effect and mechanism of fuling and Chenpi tea combined with flexible fasting technology on the health status of simple obesity patients with phlegm-dampness constitution

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200061902 ; ChiMCTR2200006355

申请注册联系人:

付小宇

研究负责人:

张成岗

Applicant:

Fu Xiaoyu

Study leader:

Zhang Chenggang

申请注册联系人电话:

Applicant telephone:

15512422496

研究负责人电话:

Study leader's telephone:

13910133213

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15512422496@163.com

研究负责人电子邮件:

Study leader's E-mail:

jxs@bucm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市房山区阳光南大街与白杨路交叉口北京中医药大学良乡校区

研究负责人通讯地址:

北京市房山区阳光南大街与白杨路交叉口北京中医药大学良乡校区

Applicant address:

Liangxiang Campus of Beijing University of Chinese Medicine, the intersection of Yangguang South Street and Baiyang Road, Fangshan District, Beijing

Study leader's address:

Liangxiang Campus of Beijing University of Chinese Medicine, the intersection of Yangguang South Street and Baiyang Road, Fangshan District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

102488

研究负责人邮政编码:

Study leader's postcode:

102488

申请人所在单位:

北京中医药大学生命科学学院

Applicant's institution:

School of Life Sciences, Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2022BZYLL05011

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

北京中医药大学伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/5/27 0:00:00

伦理委员会联系人:

李梅、赵丽红

Contact Name of the ethic committee:

Li Mei、Zhao Lihong

伦理委员会联系地址:

北京市房山区阳光南大街与白杨路交叉口北京中医药大学良乡校区

Contact Address of the ethic committee:

Liangxiang Campus of Beijing University of Chinese Medicine, the intersection of Yangguang South Street and Baiyang Road, Fangshan District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

(010)53911431

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llbgs@bucm.edu.cn

研究实施负责(组长)单位:

北京中医药大学生命科学学院

Primary sponsor:

School of Life Sciences, Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京市房山区阳光南大街与白杨路交叉口北京中医药大学良乡校区

Primary sponsor's address:

Liangxiang Campus of Beijing University of Chinese Medicine, the intersection of Yangguang South Street and Baiyang Road, Fangshan District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学

具体地址:

北京市房山区阳光南大街与白杨路交叉口北京中医药大学良乡校区

Institution
hospital:

Beijing University of Chinese Medicine

Address:

Liangxiang Campus of Beijing University of Chinese Medicine, the intersection of Yangguang South Street and Baiyang Road, Fangshan District, Beijing

经费或物资来源:

高层次人才科研启动经费资助项目

Source(s) of funding:

High-level talent scientific research start-up funding project

研究疾病:

肥胖

研究疾病代码:

Target disease:

obesity

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

(1)探究“柔性辟谷+茯苓陈皮饮”的干预方式对肥胖及痰湿体质的改善情况; (2)探究“柔性辟谷+茯苓陈皮饮”干预方式与单纯“柔性辟谷”干预的差异性; (3)将中医药手段与柔性辟谷技术联合,研究柔性辟谷技术用于慢病防控的优化方案。

Objectives of Study:

(1) To explore the improvement of obesity and phlegm-dampness constitution by the intervention method of" flexible fsting + fuling and Chenpi tea"; (2) To explore the difference between the intervention method of "flexible fasting + fuling and Chenpi tea" and the simple "flexible fasting " intervention; (3) Combine traditional Chinese medicine and flexible fasting technology to study the optimal plan for flexible fasting technology for chronic disease prevention and control.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合单纯性肥胖诊断标准; ②体质量指数:28kg/m^2≤BMI<37.5 kg/m^2; ③符合痰湿体质判定标准; ④年龄18-70周岁,性别不限; ⑤同意参与试验并签署知情同意书,且能够配合研究者完成相关资料采集患者。

Inclusion criteria

① Meet the diagnostic criteria for simple obesity; ② Body mass index: 28kg/m^2≤BMI<37.5kg/m^2; ③ Meet the phlegm-dampness constitution criteria; ④ Age 18-70 years old, gender is not limited; ⑤ Patients who agreed to participate in the trial and signed the informed consent form, and were able to cooperate with the investigator to complete the collection of relevant data.

排除标准:

①合并其他严重原发性疾病(严重的心肺肝肾等重要脏器功能不全,严重脑血管病,严重骨关节疾病如骨折、凝血功能障碍等血液系统疾病,其他影响饮食、运动的疾病等); ②合并糖尿病、痛风等需长期服药治疗的慢性疾病; ③合并其他传染性疾病或精神疾病; ④妊娠期或哺乳期妇女,及计划妊娠的妇女; ⑤无法进行正常交流者; ⑥正在参加其他临床课题实验; ⑦不适合进行禁食干预的受试者。

Exclusion criteria:

① Combined with other serious primary diseases (severe insufficiency of important organs such as heart, lung, liver and kidney, severe cerebrovascular disease, severe bone and joint diseases such as fractures, coagulation disorders and other blood system diseases, other diseases that affect diet and exercise, etc.); ② Chronic diseases such as diabetes and gout that require long-term medication; ③ Combined with other infectious diseases or mental diseases; ④ Pregnant or breastfeeding women, and women planning to become pregnant; ⑤ Those who cannot communicate normally; ⑥ Participating in other clinical subject experiments; ⑦ Subjects who are not suitable for fasting intervention.

研究实施时间:

Study execute time:

From 2022-07-25

To      2023-05-25

征募观察对象时间:

Recruiting time:

From 2022-08-01

To      2023-05-01

干预措施:

Interventions:

组别:

干预组

样本量:

150

Group:

intervention group

Sample size:

干预措施:

茯苓陈皮茶饮联合柔性辟谷技术

干预措施代码:

Intervention:

Fuling and Chenpi tea combined with flexible fasting technolog

Intervention code:

组别:

对照组

样本量:

50

Group:

control group

Sample size:

干预措施:

单纯性柔性辟谷

干预措施代码:

Intervention:

simple flexible fasting

Intervention code:

样本总量 Total sample size : 200

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学房山医院

单位级别:

三级甲等

Institution/hospital:

Fangshan Hospital of Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

体脂率

指标类型:

主要指标

Outcome:

Body fat percentage

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人体质量指数

指标类型:

主要指标

Outcome:

Body mass index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身体围度

指标类型:

次要指标

Outcome:

Body circumference

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖

指标类型:

次要指标

Outcome:

Fasting blood sugar

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

Gut flora

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血清

组织:

Sample Name:

Serum

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由独立统计师采用随机数字表法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Generate random sequence by independent statistician using random number table method

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023年12月在网络平台ResMan进行公开,网址:https://myresman.com/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish on the online platform ResMan, URL: https://myresman.com/,in December 2023

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集由纸质版CRF和电子问卷进行,采集后统一录入Excel(Microsoft)上传ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection was carried out by paper CRF and electronic questionnaires. After collection, they were uniformly entered into Excel (Microsoft) and uploaded to ResMan

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above